Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Oxytocin Effect in Adult Patients with Autism: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Author(s): Zahra Kiani, Tahereh Farkhondeh, Hamed Aramjoo, Michael Aschner, Hossein Beydokhti, Aliakbar Esmaeili, Morteza Arab-Zozani* and Saeed Samarghandian*

Volume 22, Issue 6, 2023

Published on: 13 July, 2022

Page: [906 - 915] Pages: 10

DOI: 10.2174/1871527321666220517112612

open access plus

Abstract

Introduction: The efficacy of oxytocin in the treatment of autism spectrum disorder (ASD) has not been fully characterized. This systematic review and meta-analysis study evaluated randomized controlled trials (RCTs) on the treatment of intranasally administered oxytocin for autism.

Methods: The study was conducted in accordance with the PRISMA statement. Two authors searched Scopus, PubMed/ Medline, Google Scholar, and Web of Science search engines and databases from inception through December 2020. Quality assessment was carried out by with the “ROB-2, Cochrane collaboration's tool”. The random-effects model was used for pooled analyses. I2 and Q tests were used to investigate study heterogeneity. The visual inspection of funnel plots along with Egger’s regression asymmetry test was used to assess the potential sources of publication bias.

Results: Ten RCTs were selected for the systematic review. No study corroborated the efficacy of oxytocin for the treatment of anxiety and repetitive behavior. One out of 4 studies reported clinical improvement in severity, and 1 out of 6 studies indicated improvement in social function. Our metaanalyses findings suggest that oxytocin shows no significant efficacy in the treatment of anxiety (SMD: -0.168, SE= 0.112; 95% CI: -0.387, 0.050, p = 0.132), repetitive behavior (SMD: -0.078, SE= 0.155; 95% CI: -0.382, 0.225, p = 0.614), social function (SMD: -0.018, SE= 0.133; 95% CI: -0.279, 0.242, p = 0.891) and severity (SMD: -0.084, SE= 132; 95% CI: -0.343, 0.175, p = 0.524) of autism. No significant heterogeneity nor publication bias were observed between studies.

Conclusion: Our findings failed to corroborate the efficacy of oxytocin in the treatment of ASD. Nonetheless, given the several limitations of our study, the results should be interpreted cautiously and stimulate future research on this timely topic.

Keywords: Autism spectrum disorders, anxiety, social cognition, repetitive behaviors, severity, oxytocin.

« Previous Next »
[1]
Johnson KP, Zarrinnegar P. Autism Spectrum Disorder and Sleep. Child Adolesc Psychiatr Clin N Am 2021; 30(1): 195-208.
[http://dx.doi.org/10.1016/j.chc.2020.08.012] [PMID: 33223062]
[2]
Lyall K, Croen L, Daniels J, et al. The changing epidemiology of Autism Spectrum Disorders. Annu Rev Public Health 2017; 38(1): 81-102.
[http://dx.doi.org/10.1146/annurev-publhealth-031816-044318] [PMID: 28068486]
[3]
Neggers YH. Increasing prevalence, changes in diagnostic criteria, and nutritional risk factors for autism spectrum disorders. ISRN Nutr 2014; 2014: 1-14.
[http://dx.doi.org/10.1155/2014/514026] [PMID: 24967269]
[4]
Qiu S, Lu Y, Li Y, et al. Prevalence of autism spectrum disorder in Asia: A systematic review and meta-analysis. Psychiatry Res 2020; 284: 112679.
[http://dx.doi.org/10.1016/j.psychres.2019.112679] [PMID: 31735373]
[5]
Wang C, Geng H, Liu W, Zhang G. Prenatal, perinatal, and postnatal factors associated with autism. Medicine (Baltimore) 2017; 96(18): e6696.
[http://dx.doi.org/10.1097/MD.0000000000006696] [PMID: 28471964]
[6]
Robinson EB, Neale BM, Hyman SE. Genetic research in autism spectrum disorders. Curr Opin Pediatr 2015; 27(6): 685-91.
[http://dx.doi.org/10.1097/MOP.0000000000000278] [PMID: 26371945]
[7]
Tick B, Bolton P, Happé F, Rutter M, Rijsdijk F. Heritability of autism spectrum disorders: A meta-analysis of twin studies. J Child Psychol Psychiatry 2016; 57(5): 585-95.
[http://dx.doi.org/10.1111/jcpp.12499] [PMID: 26709141]
[8]
Reichow B, Hume K, Barton EE, Boyd BA. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Libr 2018; 2018(10): CD009260.
[http://dx.doi.org/10.1002/14651858.CD009260.pub3] [PMID: 29742275]
[9]
Whalon KJ, Conroy MA, Martinez JR, Werch BL. School-based peer-related social competence interventions for children with autism spectrum disorder: A meta-analysis and descriptive review of single case research design studies. J Autism Dev Disord 2015; 45(6): 1513-31.
[http://dx.doi.org/10.1007/s10803-015-2373-1] [PMID: 25641004]
[10]
Sharma A, Shaw SR. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: A meta-analysis. J Pediatr Health Care 2012; 26(4): 291-9.
[http://dx.doi.org/10.1016/j.pedhc.2011.02.008]
[11]
Accordino RE, Kidd C, Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in autism spectrum disorder. Expert Opin Pharmacother 2016; 17(7): 937-52.
[http://dx.doi.org/10.1517/14656566.2016.1154536] [PMID: 26891879]
[12]
Lamy M, Erickson CA. Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders. Curr Probl Pediatr Adolesc Health Care 2018; 48(10): 250-64.
[http://dx.doi.org/10.1016/j.cppeds.2018.08.015] [PMID: 30262163]
[13]
Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet 2014; 383(9920): 896-910.
[http://dx.doi.org/10.1016/S0140-6736(13)61539-1] [PMID: 24074734]
[14]
Aishworiya R, Valica T, Hagerman R, Restrepo B. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics 2022. Epub ahead of print
[http://dx.doi.org/10.1007/s13311-022-01183-1] [PMID: 35029811]
[15]
Moerkerke M, Peeters M, de Vries L, et al. Endogenous Oxytocin Levels in Autism—A Meta-Analysis. Brain Sci 2021; 11(11): 1545.
[http://dx.doi.org/10.3390/brainsci11111545] [PMID: 34827545]
[16]
Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 2008; 58(4): 639-50.
[http://dx.doi.org/10.1016/j.neuron.2008.04.009] [PMID: 18498743]
[17]
Huber D, Veinante P, Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 2005; 308(5719): 245-8.
[http://dx.doi.org/10.1126/science.1105636] [PMID: 15821089]
[18]
Romano A, Tempesta B, Micioni Di Bonaventura MV, Gaetani S. From autism to eating disorders and more: The role of oxytocin in neuropsychiatric disorders. Front Neurosci 2016; 9(497): 497.
[http://dx.doi.org/10.3389/fnins.2015.00497] [PMID: 26793046]
[19]
Freeman SM, Palumbo MC, Lawrence RH, Smith AL, Goodman MM, Bales KL. Effect of age and autism spectrum disorder on oxytocin receptor density in the human basal forebrain and midbrain. Transl Psychiatry 2018; 8(1): 257.
[http://dx.doi.org/10.1038/s41398-018-0315-3] [PMID: 30514927]
[20]
Baker E, Stavropoulos KKM. The effects of oxytocin administration on individuals with ASD: Neuroimaging and behavioral evidence. Prog Mol Biol Transl Sci 2020; 173: 209-38.
[http://dx.doi.org/10.1016/bs.pmbts.2020.04.009] [PMID: 32711811]
[21]
Keller R, Basta R, Salerno L, Elia M. Autism, epilepsy, and synaptopathies: A not rare association. Neurol Sci 2017; 38(8): 1353-61.
[http://dx.doi.org/10.1007/s10072-017-2974-x] [PMID: 28455770]
[22]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[23]
Spielberger C, Gorsuch R, Lushene R. STAI Manual for the State— Trait Anxiety lnventory. California: Consulting Psychologists Press Inc. 1970.
[24]
Spence SH, Barrett PM, Turner CM. Psychometric properties of the Spence Children’s Anxiety Scale with young adolescents. J Anxiety Disord 2003; 17(6): 605-25.
[http://dx.doi.org/10.1016/S0887-6185(02)00236-0] [PMID: 14624814]
[25]
Gillath O, Hart J, Noftle EE, Stockdale GD. Development and validation of a state adult attachment measure (SAAM). J Res Pers 2009; 43(3): 362-73.
[http://dx.doi.org/10.1016/j.jrp.2008.12.009]
[26]
Schopler E, Reichler R, Renner B. Childhood Autism Rating Scale (CARS). Los Angeles, CA: West Psychol Serv 1988; p. 59804.
[27]
Guy W. ECDEU Assessment manual for psychopharmacology, revised US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health 1976; pp. 76-338.
[28]
Lam KSL, Aman MG. The repetitive behavior scale-revised: Independent validation in individuals with autism spectrum disorders. J Autism Dev Disord 2007; 37(5): 855-66.
[http://dx.doi.org/10.1007/s10803-006-0213-z] [PMID: 17048092]
[29]
Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012; 2(12): e202.
[http://dx.doi.org/10.1038/tp.2012.124] [PMID: 23233021]
[30]
Constantino J, Gruber C. Social responsive scale (SRS) manual. Los Angeles, CA: Western Psychological Services 2005.
[31]
Anme T, Watanabe T, Tokutake K, et al. A pilot study of social competence assessment using interaction rating scale advanced. ISRN Pediatr 2011; 2011: 1-6.
[http://dx.doi.org/10.5402/2011/272913] [PMID: 22389772]
[32]
Bernaerts S, Boets B, Bosmans G, Steyaert J, Alaerts K. Behavioral effects of multiple-dose oxytocin treatment in autism: A randomized, placebo-controlled trial with long-term follow-up. Mol Autism 2020; 11(1): 6.
[http://dx.doi.org/10.1186/s13229-020-0313-1] [PMID: 31969977]
[33]
Kosaka H, Okamoto Y, Munesue T, et al. Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: A 24-week randomized clinical trial. Transl Psychiatry 2016; 6(8): e872.
[http://dx.doi.org/10.1038/tp.2016.152] [PMID: 27552585]
[34]
Parker KJ, Oztan O, Libove RA, et al. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci USA 2017; 114(30): 8119-24.
[http://dx.doi.org/10.1073/pnas.1705521114] [PMID: 28696286]
[35]
Toolan C, Holbrook A, Schlink A, Shire S, Brady N, Kasari C. Using the Clinical Global Impression scale to assess social communication change in minimally verbal children with autism spectrum disorder. Autism Res 2021; 15(2): 284-95.
[http://dx.doi.org/10.1002/aur.2638] [PMID: 34800004]
[36]
Quintana DS, Westlye LT, Hope S, et al. Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: A randomized placebo-controlled double-blind crossover trial. Transl Psychiatry 2017; 7(5): e1136.
[http://dx.doi.org/10.1038/tp.2017.103] [PMID: 28534875]
[37]
Yamasue H, Okada T, Munesue T, et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: A randomized clinical trial. Mol Psychiatry 2020; 25(8): 1849-58.
[http://dx.doi.org/10.1038/s41380-018-0097-2] [PMID: 29955161]
[38]
Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial. Mol Autism 2012; 3(1): 16.
[http://dx.doi.org/10.1186/2040-2392-3-16] [PMID: 23216716]
[39]
Guastella AJ, Gray KM, Rinehart NJ, et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: A randomized controlled trial. J Child Psychol Psychiatry 2015; 56(4): 444-52.
[http://dx.doi.org/10.1111/jcpp.12305] [PMID: 25087908]
[40]
Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial. Mol Psychiatry 2016; 21(9): 1225-31.
[http://dx.doi.org/10.1038/mp.2015.162] [PMID: 26503762]
[41]
Dadds MR, MacDonald E, Cauchi A, Williams K, Levy F, Brennan J. Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial. J Autism Dev Disord 2014; 44(3): 521-31.
[http://dx.doi.org/10.1007/s10803-013-1899-3] [PMID: 23888359]
[42]
Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. Social amnesia in mice lacking the oxytocin gene. Nat Genet 2000; 25(3): 284-8.
[http://dx.doi.org/10.1038/77040] [PMID: 10888874]
[43]
Popik P, Vetulani J, van Ree JM. Low doses of oxytocin facilitate social recognition in rats. Psychopharmacology (Berl) 1992; 106(1): 71-4.
[http://dx.doi.org/10.1007/BF02253591] [PMID: 1738795]
[44]
Witt DM, Winslow JT, Insel TR. Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacol Biochem Behav 1992; 43(3): 855-61.
[http://dx.doi.org/10.1016/0091-3057(92)90418-F] [PMID: 1448480]
[45]
Windle RJ, Kershaw YM, Shanks N, Wood SA, Lightman SL, Ingram CD. Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of hypothalamo-pituitary-adrenal activity. J Neurosci 2004; 24(12): 2974-82.
[http://dx.doi.org/10.1523/JNEUROSCI.3432-03.2004] [PMID: 15044536]
[46]
Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009; 34(6): 917-23.
[http://dx.doi.org/10.1016/j.psyneuen.2009.01.005] [PMID: 19246160]
[47]
Yoshida M, Takayanagi Y, Inoue K, et al. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci 2009; 29(7): 2259-71.
[http://dx.doi.org/10.1523/JNEUROSCI.5593-08.2009] [PMID: 19228979]
[48]
Melis MR, Argiolas A. Central control of penile erection: A re-visitation of the role of oxytocin and its interaction with dopamine and glutamic acid in male rats. Neurosci Biobehav Rev 2011; 35(3): 939-55.
[http://dx.doi.org/10.1016/j.neubiorev.2010.10.014] [PMID: 21050872]
[49]
Liu Y, Wang ZX. Nucleus accumbens oxytocin and dopamine interact to regulate pair bond formation in female prairie voles. Neuroscience 2003; 121(3): 537-44.
[http://dx.doi.org/10.1016/S0306-4522(03)00555-4] [PMID: 14568015]
[50]
Ooi YP, Weng S-J, Kossowsky J, Gerger H, Sung M. Oxytocin and autism spectrum disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry 2017; 50(1): 5-13.
[PMID: 27574858]
[51]
Preti A, Melis M, Siddi S, Vellante M, Doneddu G, Fadda R. Oxytocin and autism: A systematic review of randomized controlled trials. J Child Adolesc Psychopharmacol 2014; 24(2): 54-68.
[http://dx.doi.org/10.1089/cap.2013.0040] [PMID: 24679173]
[52]
Sanna F, Argiolas A, Melis MR. Oxytocin-induced yawning: Sites of action in the brain and interaction with mesolimbic/] mesocortical and incertohypothalamic dopaminergic neurons in male rats. Horm Behav 2012; 62(4): 505-14.
[http://dx.doi.org/10.1016/j.yhbeh.2012.08.010] [PMID: 22981942]
[53]
Churchland PS, Winkielman P. Modulating social behavior with oxytocin: How does it work? What does it mean? Horm Behav 2012; 61(3): 392-9.
[http://dx.doi.org/10.1016/j.yhbeh.2011.12.003] [PMID: 22197271]
[54]
Labuschagne I, Phan KL, Wood A, et al. Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. Int J Neuropsychopharmacol 2012; 15(7): 883-96.
[http://dx.doi.org/10.1017/S1461145711001489] [PMID: 21996304]
[55]
Domes G, Heinrichs M, Gläscher J, Büchel C, Braus DF, Herpertz SC. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 2007; 62(10): 1187-90.
[http://dx.doi.org/10.1016/j.biopsych.2007.03.025] [PMID: 17617382]
[56]
LoParo D, Waldman ID. The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: A meta-analysis. Mol Psychiatry 2015; 20(5): 640-6.
[http://dx.doi.org/10.1038/mp.2014.77] [PMID: 25092245]
[57]
Bakermans-Kranenburg M, Van Ijzendoorn M. Sniffing around oxytocin: Review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl Psychiatry 2013; 3(5): e258.
[http://dx.doi.org/10.1038/tp.2013.34]
[58]
Shahrestani S, Kemp AH, Guastella AJ. The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: A meta-analysis. Neuropsychopharmacology 2013; 38(10): 1929-36.
[http://dx.doi.org/10.1038/npp.2013.86] [PMID: 23575742]
[59]
Van IJzendoorn MH, Bakermans-Kranenburg MJ. A sniff of trust: Meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Psychoneuroendocrinology 2012; 37(3): 438-43.
[http://dx.doi.org/10.1016/j.psyneuen.2011.07.008] [PMID: 21802859]
[60]
Baribeau DA, Anagnostou E. Social communication is an emerging target for pharmacotherapy in autism spectrum disorder—A review of the literature on potential agents. J Can Acad Child Adolesc Psychiatry 2014; 23(1): 20-30.
[61]
MacDonald K, Feifel D. Helping oxytocin deliver: Considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci 2013; 7: 35.
[http://dx.doi.org/10.3389/fnins.2013.00035] [PMID: 23508240]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy